Jenneke Leentjens1, Matthijs Kox2, Robin Stokman2, Jelle Gerretsen2, Dimitri A Diavatopoulos3, Reinout van Crevel4, Guus F Rimmelzwaan5, Peter Pickkers2, Mihai G Netea4. 1. Department of Internal Medicine Department of Intensive Care Medicine, Radboud Institute for Health Sciences. 2. Department of Intensive Care Medicine, Radboud Institute for Health Sciences. 3. Laboratory of Pediatric Infectious Diseases, Radboud Institute for Molecular Life Sciences, Nijmegen. 4. Department of Internal Medicine. 5. Erasmus MC Department of Viroscience, Rotterdam, The Netherlands.
Abstract
BACKGROUND: Influenza-related morbidity and mortality remain high. Seasonal vaccination is the backbone of influenza management but does not always result in protective antibody titers. Nonspecific effects of BCG vaccination related to enhanced function of myeloid antigen-presenting cells have been reported. We hypothesized that BCG vaccination could also enhance immune responses to influenza vaccination. METHODS:Healthy volunteers received either live attenuated BCG vaccine (n = 20) or placebo (n = 20) in a randomized fashion, followed by intramuscular injection of trivalent influenza vaccine 14 days later. Hemagglutination-inhibiting (HI) antibodies and cellular immunity measured by ex vivo leukocyte responses were assessed. RESULTS: In BCG-vaccinated subjects, HI antibody responses against the 2009 pandemic influenza A(H1N1) vaccine strain were significantly enhanced, compared with the placebo group, and there was a trend toward more-rapid seroconversion. Additionally, apart from enhanced proinflammatory leukocyte responses following BCG vaccination, nonspecific effects of influenza vaccination were also observed, with modulation of cytokine responses against unrelated pathogens. CONCLUSIONS:BCG vaccination prior to influenza vaccination results in a more pronounced increase and accelerated induction of functional antibody responses against the 2009 pandemic influenza A(H1N1) vaccine strain. These results may have implications for the design of vaccination strategies and could lead to improvement of vaccination efficacy.
RCT Entities:
BACKGROUND: Influenza-related morbidity and mortality remain high. Seasonal vaccination is the backbone of influenza management but does not always result in protective antibody titers. Nonspecific effects of BCG vaccination related to enhanced function of myeloid antigen-presenting cells have been reported. We hypothesized that BCG vaccination could also enhance immune responses to influenza vaccination. METHODS: Healthy volunteers received either live attenuated BCG vaccine (n = 20) or placebo (n = 20) in a randomized fashion, followed by intramuscular injection of trivalent influenza vaccine 14 days later. Hemagglutination-inhibiting (HI) antibodies and cellular immunity measured by ex vivo leukocyte responses were assessed. RESULTS: In BCG-vaccinated subjects, HI antibody responses against the 2009 pandemic influenza A(H1N1) vaccine strain were significantly enhanced, compared with the placebo group, and there was a trend toward more-rapid seroconversion. Additionally, apart from enhanced proinflammatory leukocyte responses following BCG vaccination, nonspecific effects of influenza vaccination were also observed, with modulation of cytokine responses against unrelated pathogens. CONCLUSIONS: BCG vaccination prior to influenza vaccination results in a more pronounced increase and accelerated induction of functional antibody responses against the 2009 pandemic influenza A(H1N1) vaccine strain. These results may have implications for the design of vaccination strategies and could lead to improvement of vaccination efficacy.
Authors: Bram Priem; Mandy M T van Leent; Abraham J P Teunissen; Alexandros Marios Sofias; Vera P Mourits; Lisa Willemsen; Emma D Klein; Roderick S Oosterwijk; Anu E Meerwaldt; Jazz Munitz; Geoffrey Prévot; Anna Vera Verschuur; Sheqouia A Nauta; Esther M van Leeuwen; Elizabeth L Fisher; Karen A M de Jong; Yiming Zhao; Yohana C Toner; Georgios Soultanidis; Claudia Calcagno; Paul H H Bomans; Heiner Friedrich; Nico Sommerdijk; Thomas Reiner; Raphaël Duivenvoorden; Eva Zupančič; Julie S Di Martino; Ewelina Kluza; Mohammad Rashidian; Hidde L Ploegh; Rick M Dijkhuizen; Sjoerd Hak; Carlos Pérez-Medina; Jose Javier Bravo-Cordero; Menno P J de Winther; Leo A B Joosten; Andrea van Elsas; Zahi A Fayad; Alexander Rialdi; Denis Torre; Ernesto Guccione; Jordi Ochando; Mihai G Netea; Arjan W Griffioen; Willem J M Mulder Journal: Cell Date: 2020-10-29 Impact factor: 41.582
Authors: Helen S Goodridge; S Sohail Ahmed; Nigel Curtis; Tobias R Kollmann; Ofer Levy; Mihai G Netea; Andrew J Pollard; Reinout van Crevel; Christopher B Wilson Journal: Nat Rev Immunol Date: 2016-05-09 Impact factor: 53.106
Authors: Miguel Ángel Palacios-Pedrero; Albert D M E Osterhaus; Tanja Becker; Husni Elbahesh; Guus F Rimmelzwaan; Giulietta Saletti Journal: Front Immunol Date: 2021-05-12 Impact factor: 7.561